Compare BLDP & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | MYGN |
|---|---|---|
| Founded | 1979 | 1991 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.5M | 481.6M |
| IPO Year | 2009 | 1996 |
| Metric | BLDP | MYGN |
|---|---|---|
| Price | $2.37 | $4.66 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $2.24 | ★ $7.64 |
| AVG Volume (30 Days) | ★ 2.7M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $41.84 | $7.19 |
| Revenue Next Year | $14.68 | $5.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.00 | $3.76 |
| 52 Week High | $4.10 | $10.32 |
| Indicator | BLDP | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 41.35 |
| Support Level | $1.79 | $3.93 |
| Resistance Level | $2.92 | $5.63 |
| Average True Range (ATR) | 0.13 | 0.42 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 64.49 | 21.43 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from Poland followed by United States, United Kingdom, and other countries.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.